Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS20030068378 A1
Publication typeApplication
Application numberUS 10/091,062
Publication dateApr 10, 2003
Filing dateMar 5, 2002
Priority dateJan 21, 1999
Also published asCA2358524A1, CN1354656A, CN100389755C, DE69930964D1, DE69930964T2, EP1143940A2, EP1143940B1, US6552024, WO2000042992A2, WO2000042992A3
Publication number091062, 10091062, US 2003/0068378 A1, US 2003/068378 A1, US 20030068378 A1, US 20030068378A1, US 2003068378 A1, US 2003068378A1, US-A1-20030068378, US-A1-2003068378, US2003/0068378A1, US2003/068378A1, US20030068378 A1, US20030068378A1, US2003068378 A1, US2003068378A1
InventorsLi-Lan Chen, William Pfister, Donald Renn, Thitiwan Buranachokpaisan, James Osborne, Hock Tan, Li Tao
Original AssigneeLavipharm Laboratories Inc.
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Compositions and methods for mucosal delivery
US 20030068378 A1
Abstract
Mucosal surface-coat-forming film dosage units containing a water-soluble hydrocolloid, an effective dose of a sexual dysfunction active agent and a mucosal adhesion enhancer, wherein the mucosal adhesion enhancer is a starch graft copolymer.
Images(6)
Previous page
Next page
Claims(51)
What is claimed:
1. A dosage unit comprising a mucosal surface-coat-forming film, wherein the mucosal surface-coat-forming film comprises a water-soluble hydrocolloid, an effective dose of a sexual dysfunction active agent and a mucosal adhesion enhancer, wherein the mucosal adhesion enhancer is a starch graft copolymer.
2. The dosage unit of claim 1, wherein the mucosal adhesion enhancer is a copolymer of starch and acrylic acid.
3. The dosage unit of claim 1, wherein the film exhibits a dry tack value of less than 3.5 g.
4. The dosage unit of claim 1, wherein the film exhibits a dry tack value of less than 2.0 g.
5. The dosage unit of claim 1, wherein the film exhibits a wet tack value of greater than 35 g.
6. The dosage unit of claim 1, wherein the water-soluble hydrocolloid exhibits a gelation temperature that is greater than 70° C. for a 2% polymer solution.
7. The dosage unit of claim 1, wherein the water-soluble hydrocolloid exhibits a hydration rate in 24 hours of 5-20% at 75% humidity at room temperature.
8. The dosage unit of claim 1, wherein the water-soluble hydrocolloid is a polymer selected from the group consisting of a natural, semi-natural and synthetic biopolymer.
9. The dosage unit of claim 8, wherein the water-soluble hydrocolloid is selected from the group consisting of a polysaccharade and a polypeptide.
10. The dosage unit of claim 8, wherein the water-soluble hydrocolloid comprises a hydroxypropylmethylcellulose polymer.
11. The dosage unit of claim 10, wherein the hydroxypropylmethylcellulose polymer has a molecular weight of less than 200,000 Daltons.
12. The dosage unit of claim 1, wherein the film further comprises at least one of an emulsifier, a plasticizer, a taste modifying agent, a water soluble inert filler, a preservative, a coloring agent, a stabilizer and a buffering agent.
13. The dosage unit of claim 1, wherein the film further comprises an emulsifier present at a concentration in the range of 0.1 to 10 wt % of the dosage unit.
14. The dosage unit of claim 1, wherein the film further comprises a taste modifying agent comprising at least one of a sweetening agent, a flavoring agent and a taste masking agent.
15. The dosage unit of claim 1, wherein the film further comprises a water soluble inert filler present at a concentration in the range of 0.5 to 50 wt % of the dosage unit.
16. The dosage unit of claim 1, wherein the film further comprises a preservative present at a concentration in the range of 0.01 to 10 wt % of the dosage unit.
17. The dosage unit of claim 1, wherein the active agent is present at a concentration in the range of 0.01 to 75 wt % of the dosage unit.
19. The dosage unit of claim 1, wherein the sexual dysfunction active agent is sildenafil citrate.
20. The dosage unit of claim 1, wherein the film has a dry film thickness in the range of 1 to 20 mil.
21. The dosage unit of claim 20, wherein the film has a dry film thickness of less than 10 mils.
22. The dosage unit of claim 1, wherein the film exhibits a tensile strength greater than 1500 psi.
23. The dosage unit of claim 1, wherein the film exhibits a % elongation of less than 20%.
24. The dosage unit of claim 1, wherein the film exhibits a modulus in the range of 35,000 to 300,000 psi.
24. The dosage unit of claim 1, wherein the film exhibits a dissolution time in the range of 10 to 600 seconds upon application to an oral mucosal surface.
25. The dosage unit of claim 1, wherein the film exhibits a dissolution time in the range of 1 to 300 seconds upon application to an oral mucosal surface.
26. The dosage unit of claim 24, wherein the film exhibits a tensile strength greater than 1,500 psi, a % elongation of less than 20% and a disintegration time in the range from 1 to 300 seconds upon application to an oral mucosal surface.
27. The dosage unit of claim 1, wherein the active agent is encapsulated within a polymer, wherein the polymer is chemically or physically distinct from the hydrocolloid.
28. The dosage unit of claim 1, wherein the dosage unit comprises at least two active agents.
29. The dosage unit of claim 1, wherein the mucosal adhesion enhancer is present at a concentration of up to 50%.
30. A dosage unit comprising a mucosal surface-coat-forming film, wherein the mucosal surface-coat-forming film comprises a water-soluble hydrocolloid, an effective dose of a sexual dysfunction active agent and a mucosal adhesion enhancer; wherein the active agent is encapsulated within a polymer which is chemically or physically distinct from the hydrocolloid; wherein the mucosal adhesion enhancer is a starch graft copolymer; wherein the film exhibits a dry tack value of less than 3.5 g, a wet tack of greater than 35 g, a gelation temperature that is greater than 70° C. for a 2% polymer solution, a dry film thickness of not more than 20 mil, a water content of 0.5 to 10%, a tensile strength greater than 1500 psi, a modulus in the range of 35,000 to 300,000 psi, a % elongation of less than 20%, a tear propagation resistance of 0.001 to 1 N, and a dissolution time on not more than 600 seconds upon application to an oral mucosal surface.
31. The dosage unit of claim 30, wherein the mucosal adhesion enhancer is a copolymer of starch and acrylic acid.
32. The dosage unit of claim 30, wherein the film exhibits a dry tack value of less than 2.0 g.
33. The dosage unit of claim 30, wherein the water-soluble hydrocolloid exhibits a hydration rate in 24 hours of 5-20% at 75% humidity at room temperature.
34. The dosage unit of claim 30, wherein the water-soluble hydrocolloid is a polymer selected from the group consisting of a natural, semi-natural and synthetic biopolymer.
35. The dosage unit of claim 34, wherein the water-soluble hydrocolloid is selected from the group consisting of a polysaccharade and a polypeptide.
36. The dosage unit of claim 34, wherein the water-soluble hydrocolloid comprises a hydroxypropylmethylcellulose polymer.
37. The dosage unit of claim 36, wherein the hydroxypropylmethylcellulose polymer has a molecular weight of less than 200,000 Daltons.
38. The dosage unit of claim 30, wherein the film further comprises at least one of an emulsifier, a plasticizer, a taste modifying agent, a water soluble inert filler, a preservative, a coloring agent, a stabilizer and a buffering agent.
39. The dosage unit of claim 30, wherein the film further comprises an emulsifier present at a concentration in the range of 0.1 to 10 wt % of the dosage unit.
40. The dosage unit of claim 30, wherein the film further comprises a taste modifying agent comprising at least one of a sweetening agent, a flavoring agent and a taste masking agent.
41. The dosage unit of claim 30, wherein the film further comprises a water soluble inert filler present at a concentration in the range of 0.5 to 50 wt % of the dosage unit.
42. The dosage unit of claim 30, wherein the film further comprises a preservative present at a concentration in the range of 0.01 to 10 wt % of the dosage unit.
43. The dosage unit of claim 30, wherein the active agent is present at a concentration in the range of 0.01 to 75 wt % of the dosage unit.
44. The dosage unit of claim 30, wherein the sexual dysfunction active agent is sildenafil citrate.
45. The dosage unit of claim 30, wherein the film has a dry film thickness in the range of 1 to 20 mil.
46. The dosage unit of claim 45, wherein the film has a dry film thickness of less than 10 mils.
47. The dosage unit of claim 30, wherein the film exhibits a dissolution time in the range of 10 to 600 seconds upon application to an oral mucosal surface.
48. The dosage unit of claim 30, wherein the film further exhibits a dissintegration time in the range of 1 to 300 seconds upon application to an oral mucosal surface.
49. The dosage unit of claim 30, wherein the active agent is encapsulated within a polymer, wherein the polymer is chemically or physically distinct from the hydrocolloid.
50. The dosage unit of claim 30, wherein the dosage unit comprises at least two active agents.
51. The dosage unit of claim 30, wherein the mucosal adhesion enhancer is present at a concentration of up to 50%.
Description
  • [0001]
    This Application is a continuation of U.S. patent application Ser. No. 09/619,899, filed Jul. 19, 2000, which application is a continuation-in-part of U.S. patent application Ser. No. 09/434,878, filed Nov. 5, 1999, which claims priority to U.S. Provisional Application Ser. No. 60/116,823, filed Jan. 21, 1999. The disclosures of each of the noted applications are incorporated herein by reference as if set forth herein in their entireties.
  • [0002]
    The present invention is directed to a device and method for administering sexual dysfunction active agents in a dissolving film configuration.
  • [0003]
    Many pharmaceutical dosage forms are administrated orally in the form of solid shaped articles such as tablets, pills, caplets and capsules that retain their shape under moderate pressure. Generally these dosage forms are designed to be swallowed whole or chewed to deliver the medication with adequate amounts of liquid. Some patients, particularly pediatric and geriatric patients, have difficulty swallowing or chewing solid dosage forms. Certain patients such as children or animals resist taking medication, and may try to hide a solid pill in order to spit it out later. In addition, many pediatric and geriatric patients are unwilling to take a solid dosage form because the active agent is difficult to swallow or is retained in the pharynx or gullet even when liquids are consumed with the dosage unit. Furthermore, the availability of liquids at the time of administering medications may be limited for certain patients and may be restricted for certain diseases and/or treatments. Chewable tablets provide some advantages over the conventional tablets. However, they are not suitable for children wearing braces and the taste of the medication may be unpleasant and difficult to mask in a chewable tablet. At the same time, water may be still required for the administration of chewable tablets.
  • [0004]
    In addition, the standard oral dosage forms, such as tablets, pills, caplets, and capsules, are designed for short residence time in the mouth. Absorption of the agent from these dosage forms occurs in the gastrointestinal (GI) tract, after the agent has separated from the dosage form and dissolved in the gastric fluids. For some active agents, it is desirable to achieve absorption through the oral mucosal tissues in order to accelerate onset of the therapeutic effect.
  • [0005]
    Many active agents are poorly absorbed, even after they are dispersed in the stomach, because of low solubility or slow dissolution rate in the gastric fluids. Tablets may be formulated so as to be quick dissolving. These tablets are commonly placed on the tongue and disintegrate rapidly in the oral cavity. However, these dosage units are not fixed to a mucosal surface and may move around in the mouth. Consequently, they do not overcome a risk associated with choking or gagging that occurs with subjects having limited control of their swallowing reflexes. However, once placed in the mouth, these tablets dissolve rapidly in the saliva to provide a liquid formulation which is then swallowed. Quick dissolving tablets may be formed from a particulate support matrix containing the therapeutic agent, where the particulate support matrix is a protein (U.S. Pat. Nos. 5,807,576, 5,635,210, 5,595,761). Alternatively, the tablet maybe formed from a laminate with several layers and an outer coating (JP 100535518). Tablets have also been manufactured from shearform matrices which are substantially amorphous sugar formed when crystalline sugar is subjected to heat and shear (WO 95/07194; WO 95/35293). Other methods of forming quick dissolving tablets include wet granulation methods (EP 0627 218) and dry granulation methods (EP 0124027A1) and by freeze-drying techniques (EP 0084705A2). Generally, quick dissolving tablets are formed using complex multi-step manufacturing processes. In addition, these tablets may have poor mechanical strength, are fragile and friable and have insufficient holding capacity for active ingredients (U.S. Pat. No. 5,720,974) and may be difficult to store and handle.
  • [0006]
    Therapeutic compounds are sometimes provided as powders or granules which may be difficult to swallow and cause unpleasant sensations in the mouth. Furthermore, many quick dissolving tablets contain particulates (>25 microns) which leave a “gritty” and unpleasant taste in the mouth. In the elderly, powders may cause choking and discomfort associated with trapping of granules in dentures. Powders and granules are generally packaged in a sealed pouch which requires tearing before use. This causes problems for geriatric patients and those suffering from arthritis in the fingers as well as for children. Consequently, problems of spillage of the contents arise in this group of patients. Furthermore, these oral preparations should be taken with water which for certain patients are inconvenient and may cause reduced patient compliance.
  • [0007]
    Liquid, syrups or suspensions are an alternative to solid dosage forms and are considered desirable for pediatric and geriatric patients who have problems in swallowing tablets. However, these dosage forms are often difficult to measure accurately and administer easily. Liquid formulations deteriorate rapidly upon exposure to heat or atmosphere and consequently have a relatively short shelf life. Furthermore, liquid formulations require a relatively large volume and-are bulky to store.
  • [0008]
    In addition to solid and liquid dosage forms, rapidly dissolving buccal/oral delivery systems have been developed. These systems are commonly freeze dried preparations which are more expensive to manufacture as compared to tablets (U.S. Pat. No. 5,648,093). Furthermore, freeze dried preparations are brittle and fragile when handled and must be kept in dry conditions to avoid disintegration. The instability of freeze-dried preparations has been reduced somewhat by the addition of mannitol (U.S. Pat. No. 4,946,684). WO 9820862 reports a film that is formed according to a method that does not utilize freeze drying and avoids problems described in the art such as rigidity of the films, delayed softening and poor solubility in the mouth (U.S. Pat. No. 4,876,092; EP 0200508; EPO 381194; CA-PS 1-26331; DE 2449865.5; DE 3630603; EP 0452446 and EP 0219762). However, the film described in WO 9820862 relies on the use of at least two different non-ionic surfactants to achieve immediate wettability.
  • [0009]
    It is desirable that a dosage unit should provide a non-invasive, effective and economic means to deliver an active agent to the target site. Where the target site is the plasma, additional issues arise concerning the rate of delivery of the active agent to that site as measured by bioavailability. For many types of active agent, fast onset of the therapeutic effect is desirable. Traditional oral dosages, such as tablets, are limited in onset time by the rate of absorption in the gastrointestinal tract. Formulations have been developed which, when applied in the mouth, lead to faster onset that the traditional oral dosages because they target the oral mucosa. These formulations include dosage units containing 75%-90% polyethylene glycol that melt at body temperature, in the mouth.( U.S. Pat. Nos. 5,004,601 and 5,135,752) Other formulations include liquid forms, lozenges or tablets that are administered sublingually or by a sweetened matrix on a stick. (U.S. Pat. No. 5,770,606, Streisand et al. and Zhang et al., Christie et al., Sasaki et al.). Whereas the above references address the delivery route, they do not address the problems of bioavailability that arise from poor solubility or low dissolution rate.
  • [0010]
    A delivery device that addresses the above limitations would represent a desirable improvement on existing delivery systems.
  • SUMMARY OF THE INVENTION
  • [0011]
    A novel dosage unit-and its method of manufacture and use is provided. In an embodiment, the dosage unit includes a water-soluble hydrocolloid, mucosal surface-coatforming film, such film including an effective dose of an active agent.
  • [0012]
    In an embodiment of the invention, the hydrocolloid includes a polymer selected from the group consisting of a natural, semi-natural and synthetic biopolymer being exemplified by a polysaccharide and a polypeptide. In addition to the hydrocolloid, the film may further include one or more of an emulsifier, a plasticizer, a taste modifying agent, a water soluble inert filler, a preservative, a buffering agent, a coloring agent, a permeation enhancer, and a stabilizer. The film may further include an active agent selected from the group consisting of a therapeutic agent, a dietary supplement and a hygiene aid. Embodiments of the invention utilize effective amounts of sildenafil citrate, nicotine, hydromorphone, oxybutynine or estradiol as active agents in the dosage unit. The active agent may be encapsulated within a second polymer having dissolution properties that are different from those of the hydrocolloid. More than one active agent may be included in the film. In an embodiment of the invention, the emulsifier may have a concentration of 0.1-10%w. The water inert filler may include a concentration range of 0.5-50% and the preservative may include a concentration range of 0.01-10%. A mucosal adhesion enhancer such as starch graft copolymer may be included in the dosage unit.
  • [0013]
    In embodiments of the invention, the dosage unit may further include any of the following features: a dry film thickness in the range of 1-20 mil, more particularly less than 10 mils, a dry tack value of less than 3.5 g, more particular less than 2 g, a wet tack value of greater than 35 g, a tensile strength greater than 1500psi, a modulus in the range of 35,000-300,000 psi, a tear propagation resistance in the range 0.0001N-1N, a disintegration time in a range from 1-300 seconds, a dissolution time in a range from 10-600 seconds, and a percentage elongation less than 20%.
  • [0014]
    In embodiments of the invention, methods are provided for making a dosage unit, that include in one embodiment, dissolving a hydrocolloid in a solvent so as to form a substantially homogeneous preparation; adding to the hydrocolloid preparation, an active agent and at least one reagent selected from the group consisting of an emulsifier, a plasticizer, a taste modifier, a water soluble inert filler, a coloring agent, a preservative, a permeation enhancer, a stabilizer and a buffering agent to form a coatable mixture; and forming a mucosal surface-coat forming film from the mixture for packaging as a dosage unit. The method may further include the step of coating the mixture onto a backing film. In a further embodiment, the reagents including: a hydrocolloid, an active agent, and at least one reagent selected from the group consisting of an emulsifier, a plasticizer, a taste modifier, a water soluble inert filler, a coloring agent, a preservative, a permeation enhancer, a stabilizer, and a buffering agent, may be combined in any order in a vessel having a heating source and a mechanical mixing device, the combined ingredients being mixed during and after the addition of the ingredients to the vessel, an effective amount of heat being applied for melting a substantial portion of the mixture. The mixture may then be formed into a film in a dry extrusion process.
  • [0015]
    In an embodiment of the invention, a method is provided for administering an active agent to a subject, that includes obtaining a water-soluble hydrocolloid, mucosal surface-coat forming film, such film including an effective dose of an active agent; and placing the film on a mucosal surface coat forming film in the subject; so as to release the active agent.
  • [0016]
    In a further embodiment of the invention, a dosage unit is provided that includes a water soluble hydrocolloid and an effective dose of sildenafil citrate in a muco sal-surface contacting film. More particularly, an effective dose of sildenafil citrate is formed into a solid dispersion with xylitol for treating erectile dysfunction. The sildenafil/xylitol dispersion may be mixed with at least one reagent selected from the group consisting of an emulsifier, a plasticizer, a taste modifier, a coloring agent, a preservative, a permeation enhancer, a stabilizer and a buffering agent. The solid dispersion of sildenafil and xylitol may arise at a ratio of 9 parts sildenafil to one part xylitol. According to embodiments of the invention directed to a dosage unit and method of making a dosage unit suitable for erectile dysfunction, the water solubility of sildenafil in the solid dispersion is at least 20 mg/ml, more particularly about 50 mg/ml. More particularly, the film may be capable of completely dissolution at the oral mucosal surface within 10-600 seconds.
  • BRIEF DESCRIPTION OF THE FIGURES
  • [0017]
    There are shown in the drawings certain exemplary embodiments of the present invention as presently preferred. It should be understood that the present invention is not limited to the embodiments disclosed as examples, and is capable of variation within the spirit and scope of the appended claims.
  • [0018]
    [0018]FIG. 1 shows possible application sites in the oral cavity for the inventive dosage unit. (1) is the upper lip; (2) is the gingiva; (3) is the hard palate; (4) is the cheek; (5) is the lingual; (6) is the sublingual; (7) is the lower lip;
  • [0019]
    [0019]FIG. 2 illustrates one manufacturing process for the dosage unit. (8) is the mixing and degassing tank; (9) is the coating slot with thickness controller; (10) is the polyester backing belt; (11) is the drying oven with aeration controller; (12) is the intraoral film; (13) is the die cutting and (14) is the intraoral unit dose;
  • [0020]
    [0020]FIG. 3 shows examples of packaging and dispensing devices for the intraoral delivery system. (15) is a heat sealed single pouch; (16) is a multi-unit blister card; (17) is a multi-unit dispensing pack, 17(a) the container snap and 17(b) the lid closure; (18) is a multiunit roll-type dispenser cylinder; (19) is a perforated film strip; and (20) is a single dose film;
  • [0021]
    [0021]FIG. 4 demonstrates the disintegration and dissolution time of the intraoral delivery system as a function of thickness.---- is disintegration time and -- ∘-- is dissolving time;
  • [0022]
    [0022]FIG. 5 shows the release profiles of -- ▾--- nicotine, -- ∇-- oxybutynin, ---- hydromorphone and --∘- estradiol; and,
  • [0023]
    [0023]FIG. 6 shows the pharmacokinetics in six subjects after administration of a dissolving film sildenafil formulation and after administration of the commercial tablet containing the same dosage of sildenafil. Sildenafil film --▾-- Viagra --∇--.
  • DETAILED DESCRIPTION OF INVENTION
  • [0024]
    Delivery of active agents in solid form via the mouth causes problems to patients who may choke on the dosage unit. This effect is caused at least in part by the mobility of the dosage unit within the mouth. We have developed a new class of dosage units which are not mobile in the mouth because on contact with the moist mucosal surface, the film becomes a coating that adheres to the mucosal surface and then disintegrates and dissolves over a time frame controlled in the design of the dosage. The dosage unit, in an embodiment of the invention, is in the form of a flexible, non-tacky, dry conveniently packaged film. Once removed from the package and placed on a mucosal surface, the mucosal surface-coat forming film hydrates substantially immediately to form a coating on the moist surface of the mucous membrane and then disintegrates and dissolves to release the active agent from the film.
  • [0025]
    The dosage unit may release the active agent over a period of time that is determined by a number of different factors. These factors include the dimensions of the film, the concentration of the active agent, the solubility of the agent at the mucosal surface and how the agent is dispersed throughout the film. The thickness of the film is a factor in determining the rate of dissolution. A thick film will dissolve more slowly than an otherwise similar thin film. A thick film may be desirable for its holding capacity for active agents that are required in high dosages. Although the surface area of a film can be adjusted up to about 5 square centimeters, increased thickness may also be desirable for purposes of achieving effective active agent dosages. The active agent can form a solid dispersion with a water soluble inert filler for purposes of increasing the solubility of the agent when released from the film thereby enhancing bioavailability of the active agent. This is exemplified here by sildenafil which is incorporated in a film with a water soluble inert filler, for example, xylitol, which has been found here to enhance the bioavailability of this agent. Solubilizing agents that are well known in the art may be included in the film. The extent of uptake of the active agent from the dosage unit at the mucosal surface can be controlled by the dissolution rate of the film. A dissolving film will release the active agent and this in turn will cause the active agent to be swallowed and taken up in the GI tract. In contrast, slow release of the active agent at the mucosal surface will give rise to increased uptake by the mucosal surface. A further parameter governing the release of an active agent at the mucosal surface is the manner in which the agent is dispersed in the film. For example, the agent may be dispersed as colloidal particles or microencapsulated within the film or alternatively may be mixed throughout the film as a reagent during casting.
  • [0026]
    The dosage unit of the invention may be used as a vehicle for delivering a wide range of active agents. For example, the active agent may be a small molecule, a protein, a nucleic acid including antisense molecules or other biological or synthetic molecules.
  • [0027]
    The term “mucosal surface-coat-forming” as applied to a film as used in this description and in the following claims unless specified otherwise, means a film that coats the mucosal surface on contact, and may not thereafter be manually recovered or moved from the contact site; and subsequently disintegrates and dissolves so as to release the active agent. It should be noted that for purposes of the description of the invention and the claims, “mucosal surface” refers to any moist surface of the body. This includes the surfaces identified in FIG. 1. It further includes a wound surface where lymph fluid bathes the tissue surface.
  • [0028]
    Embodiments of the present invention include a process, composition and method of use for a quick dissolving film for local and systemic delivery of pharmaceutical agents to a mucosal surface in a subject. In the following text, specific reference may be made to the oral cavity by way of example. However, it is not intended to limit the scope of the invention to the oral cavity. The dosage unit of the invention may be applied to any mucosal surface as deemed appropriate for the systemic or local delivery of an active agent including vaginal, rectal, and ocular surfaces. For purposes of oral delivery, the films may be applied on lingual, sub-lingual, buccal, gingival, and palatal surfaces (FIG. 1).
  • [0029]
    For vaginal delivery of such agents as contraceptive agents including nonoxynol or anti-infectives including antifungal agents, antibacterial agents and anti-viral agents, or fragrant or hygiene agents; the film should be non-sticky when removed from the packaging but should have mucoadhesive properties when applied in the vagina. Although films containing active agents for use in the vagina have been used, they appear to have some significant drawbacks most particularly the lack of adhesive properties at the mucosal surface. This makes these films impractical to administer. (U.S. Pat. Nos. 5,380,529; 5,595,980 and 5,529,782).
  • [0030]
    Embodiments of the invention provide improved dosage forms to deliver active agents that are appropriate for all age groups and that physician, parents, patients and family members can administer easily. These dosage forms are economical to prepare and have an extended shelf life. They are easy to handle and non-tacky before administration so as to avoid disintegration prior to use and are conveniently packaged for shelf life, ease of storage and distribution. The dosage form may be administered to the subject by placing the film on a mucous surface, at which time the film becomes a mucoadhesive coating, characterized by the property that it can no longer exist in an independent form and is subsequently dispersed in solution.
  • [0031]
    Embodiments of the invention provide a delivery system for active agents and other active agents that will dissolve and completely release their contents on a moist mucosal surface for example in the oral cavity. The release of the active agent occurs without mastication or the need for intake of water. With particular reference to the oral cavity, an embodiment of the invention provides active agents that remain in the oral cavity for treatment or modification of the oral environment; for example, for periodontal disease treatment or breath-odor control. Furthermore, embodiments of the invention further provide improvements that include: improved organoleptic properties (smell and taste), and texture and feel of dosage forms intended to be placed in the oral cavity; a dosage form which “melts” in the mouth and leaves a smooth pleasant after feel following dissolution; and a prolonged retention of the active agent in the mouth following dissolution of the quick dissolving dosage form to extend the residence time of the active agent cleared from the mouth by the production of saliva and subsequent swallowing. Depending on the optimal program for a specific application of the invention, the disintegration time and the dissolution time can be controlled within a prescribed range by adjustment of the formulation and the thickness of the film. In some cases, it is desirable for release of the active agent to occur after dissolution of the film. For these applications, the active agent may be encapsulated in a material with dissolution properties that are different from those of the hydrocolloid. Encapsulation of the active agent also may be utilized to achieve masking of taste for active agents that are bitter. In some cases, two or more different active agents may be included in the film. An example where multiple active agents frequently are administered is cold medications, which often contain several active agents.
  • [0032]
    “Coating solution” is defined here and in the claims as a viscous and homogeneous mixture of hydrocolloids, active agents and other additives in a solvent. The coating solution is treated according to the method of the invention to form a film.
  • [0033]
    “Subject” is defined here and in the claims as a human or animal species.
  • [0034]
    “Thickness” is defined here and in the claims by measurements in mil (a mil=one thousandth of an inch) determined when a film is placed between two microscopic slides.
  • [0035]
    “Permeation enhancer” as defined here and in the claims is a natural or synthetic molecule which facilitates the absorption of an active agent through a mucosal surface.
  • [0036]
    “Enzyme inhibitor” as defined here and in the claims is a natural or synthetic molecule which inhibits enzymatic metabolism of an active agent in the saliva or in a mucosal tissue.
  • [0037]
    “Water Content” is defined here and in the claims as % residual water content per unit dose as measured according to the Karl Fisher method and expressed as percent of the dry weight of the film.
  • [0038]
    “The hydration rate” is defined here and in the claims as the speed of absorbing water at 25° C. and 75% relative humidity in 24 hours.
  • [0039]
    “Percentage of swelling” is defined here as a percentage of the initial volume that is increased before dissolving. In an embodiment of the invention, the percentage of swelling is less than 10% in 60 seconds.
  • [0040]
    Taste modifying agents include flavoring agents, sweetening agents and taste masking agents and are exemplified by: the essential oils or water soluble extracts of menthol, wintergreen, peppermint, sweet mint, spearmint, vanillin, cherry, chocolate, cinnamon, clove, lemon, orange, raspberry, rose, spice, violet, herbal, fruit, strawberry, grape, pineapple, peach, kiwi, papaya, mango, coconut, apple, coffee, plum, watermelon, nuts, durean, green tea, grapefruit, banana, butter, camomile, sugar, dextrose, lactose, mannitol, sucrose, xylitol, malitol, acesulfame potassium, talin, glycyrrhizin, sucralose, aspartame, saccharin, sodium saccharin, sodium cyclamate and honey.
  • [0041]
    Emulsifying agents include solubilizers and wetting agents and are exemplified by polyvinyl alcohol, sorbitan esters, cyclodextrins, benzyl benzoate, glyceryl monostearate, polyoxyethylene alkyl ethers, polyoxyethylene stearates, poloxamer, polyoxyethylene castor oil derivatives, hydrogenated vegetable oils, bile salts, polysorbates and ethanol. Plasticizers may include glycerin, sorbitol, propylene glycol, polyethylene glycol, triacetin, triethyl citrate (TEC), acetyl triethyl citrate (ATEC) and other citrate esters.
  • [0042]
    Active agents (for human and veterinary applications) include therapeutic agents, nutritional supplements and hygiene aids. The therapeutic agents are exemplified by analgesics, a-adrenergic receptor blockers, anti-Alzheimer's disease medication, antianginal, antianxiety, antiarrythmics, antiarthritics, antibiotics, anticoagulants/thrombolytics, anticonvulsants/anti-Parkinson medication, anti-depressants, anti-diabetics, anti-diarrheal, anti-epileptics, anti-fungal, anti-gout, anti-heartworm medication for dogs, anti-histamines, anti-hypertensives, anti-inflammatories, anti-infectives, antimigraines, anti-nasuants/antiemetics, anti-neoplastics/anti-tumor active agents, anti-pruitics, anti-psychotics, anti-pyretics, anti-spasmodics, anti-virals, bronchial dilators/anti-asthmatics, calcium antagonists, cardiac agents, cardiotonics, central nervous system actives, contraceptives, coronary vasodilators, cough/cold remedies, dietary supplements, including vitamins and minerals, diuretics, fertility active agents, flea control agents for animals (Ivermectin), HZ receptor antagonists, herbal actives, hormones, hypoglycemics, hypolipidemics, muscle relaxants, ovulation stimulators, peptide active agents, polypeptide active agents, proteins such as insulin, calcitonin, LHRH and the like. Sedatives and hypnotics, sexual dysfunction active agents, sleep aids, smoking cessation aids, steroids and steroidals, tranquilizers, laxatives, ophthalmic preparations, nutritional supplements, breath fresheners, breath deodorants, saliva substitutes, antigingivitis agents, anti-cavity agents, anti-plaque agents, diagnostic indicators, and local anesthetics. Also included are active agents for treatment of osteoporosis, hormone replacement, treatment of periodontal disease, antiseptics, corticosteroids, non steroidal anti inflammatory agents, antiviral agents and vaccines.
  • [0043]
    Water soluble inert fillers include mannitol, xylitol, sucrose, lactose, maltodextrin, dextran, dextrin, modified starches, dextrose, sorbitol, and dextrates. The water soluble inert fillers may be used in embodiments of the invention as inert carriers to form a high water soluble dispersion with active agents.
  • [0044]
    Buffering agents include acidulants and alkalizing agents exemplified by citric acid, fumaric acid, lactic acid, tartaric acid, malic acid, as well as sodium citrate, sodium bicarbonate and carbonate, sodium or potassium phosphate and magnesium oxide.
  • [0045]
    Coloring agents may include FD & C coloring agents, natural coloring agents, and natural juice concentrates, pigments such as titanium oxide, silicon dioxide and zinc oxide.
  • [0046]
    Stabilizers as used here and in the claims, include anti-oxidants, chelating agents, and enzyme inhibitors as exemplified by ascorbic acid, vitamin E, butylated hyroxyanisole (BHA), butylated hydroxytoluene (BHT), propyl gallate, dilauryl thiodipropionate, thiodipropionic acid, gum guaiac, citric acid, edetic acid and its salts and glutathione.
  • [0047]
    Preservatives which here include anti-microbial agents and non-organic compounds are exemplified by sodium benzoate, parabens and derivatives, sorbic acid and its salts, propionic acids and its salts, sulfur dioxide and sulfites, acetic acid and acetates, nitrites and nitrates.
  • [0048]
    The mechanical properties of the film is determined by tensile strength modulus, percent elongation (ASTM D882, standard test method for tensile properties of thin plastic sheet) and tear propagation resistance (ASTM D1938, standard test method for tear propagation resistance of plastic film and thin sheet by single tear method). The mechanical properties are measured here using standard protocols as described in Annual Book of ASTM Standards, American National Standards Institute, N.Y 1995.
  • [0049]
    The “tensile strength” (psi) is the property of film that requires a load to cause load deformation failure of film.
  • [0050]
    The “% elongation” is measured when the film snaps as sufficient force is applied so as to exceed the elastic limit.
  • [0051]
    The “release study” is the percentage of active agents released from the film as a function of time in a suitable dissolution vessel and medium under specified conditions of temperature and pH.
  • [0052]
    “Dry tack” is quantitative values for tackiness (grams) of dry film by Texture Analyzers (Model TA.XT2i with 6 mm diameter stainless steel cylinder probe) from Texture Technologies Corp. The tackiness after the addition of 10 ml of water on the same surface area is defined as the wet tack (gram) to simulate the adhesion of film upon the contact with a moist mucosal surface. In an embodiment of the invention, the dry tack ranges from 0.2-3.5 grams, with a preferred range of 0.4-2.0 grams and the wet tack is in the range of 35-150 grams with a preferred range of 40-100 grams.
  • [0053]
    “Tear propagation resistance” is defined here and in the claims as the average force (N) necessary to propagate, a tear across a film or sheet under a specified rate of extension as defined in ASTM D1938 and is interpreted from the load time chart. In a preferred embodiment of the invention, the tear resistance ranges from 0.0001N-1N with a preferred range of 0.01-1N.
  • [0054]
    “Disintegration time” is defined here and in the claims as the time (second) at which a film breaks when brought into contact with water or saliva. In an embodiment of the invention, the disintegration time ranges from 1-300 seconds.
  • [0055]
    “Dissolving time” is defined here and in the claims as the time (seconds or minutes) at which not less than 80% of the tested film is dissolved in an aqueous media or saliva. In an embodiment of the invention, the dissolution time ranges from 10-600 seconds.
  • [0056]
    “Modulus” is a measurement of stiffness of a film.
  • [0057]
    A factor that plays a significant role in determining the properties of mucosal surface-coat-forming composition is the viscosity of the hydrocolloid. The viscosity of the hydrocolloid depends on its molecular size, derivation, hydrophobicity and hydrophilicity and the presence of other additives in the formulation. A comparison of films formed from the hydrocolloid, hydroxymethylcellulose, having different viscosity values is shown in Table 9a and 9b.
  • [0058]
    In embodiments of the invention, a hydrocolloid concentration in the range of 5-99% of the dry weight of the films is provided, more particularly greater than 10%. These films have dry tack and wet tack properties that improve ease of handling and use. The low dry tack properties of the film provide for a physically attractive and easily handled film that is neither fragile nor sticky and can be easily removed from packaging and placed on a mucosal surface. The wet tack properties of the film provide the advantage of stickiness of the moistened film such that when the film is placed on the mucosa, it remains attached at that site until it dissolves. In contrast, if the wet tack is too low, the film can move in the mouth and may be swallowed before dissolving and possibly give rise to choking. Furthermore, the low moisture content and low dry tack of the film enhances the shelf-life of the film and the flexibility of the dosage forms. These properties render the films suitable for easy making, packaging, handling and application.
  • [0059]
    In an embodiment of the invention, a water soluble polymer (2% polymer solution) is selected having a gelation temperature greater than 70° C. The hydration rate of a hydrocolloid having these features is rapid with a percentage moisture absorption of polymers in the range of 5-20% at 75% humidity at room temperature. The hydration rate is selected according to the desired wettability of the film thereby obviating the need for surfactants. The wet tack of the hydrated film ranges from 35-150 grams more particularly 40-100 grams. The percentage swelling may be less than 10% within 60 seconds. The film is cast so as to have a thickness of 1-20 mil . The water content of the film ranges from 0.5-10% with a preferred range of 1-5%. In embodiments of the invention, the film may be formed using a mixture of two or more types of the same hydrocolloid that differ only in molecular weights and/or different degrees of substitution. The time of dissolution of the film is in the range of 10-600 seconds, (see FIG. 4), the time of disintegration of the film may be 1-300 seconds. The active agent in the film may be encapsulated in a polymer having different chemical or physical properties from the hydrocolloid of the film and having dissolution properties different from those of the hydrocolloid. Examples of the films formed according to the invention having properties that fall into the above ranges are provided in Table 1,3,6 and 7. The ease of handling is characterized by the dry tack of the film and the flexibility is reflected by the tensile strength, modulus, % elongation and tear resistance of the film. For example, the dry tack is in the range of 0.2-3.5 grams more particularly 0.4-2.0 grams. The tensile strength may be in the range of 1500-10,000 psi, more particularly 2000-8000, more particularly greater than 2000 psi, the modulus is in the range of 35,000-300,000 and the % elongation is less than 20% more particularly 1-10% for a film having a thickness of 2 mil. In embodiments of the invention, the hydrocolloid may be a water soluble non-gelling (at room temperature) natural polysaccharide or derivatives including pectin and derivatives, guar gum arabic, tragacanth gum, xanthan gum, gellan sodium salt, propyleneglycol alginate, starches (amylose, amylopectin), modified starches, hydroxyethyl starch, pullulan, carboxymethyl starch, gum ghatti, okra gum, karaya gum, dextrans, dextrins and maltodextrins, konjac, acemannan from aloe, locust bean gum, tara gum, quince seed gum, fenugreek seed gum, scleroglucan, gum arabic, psyllium seed gum, tamarind gum, oat gum, quince seed gum, carrageenans, scleraglucan, succinoglucan, larch arabinogalactan, flaxseed gum, chondroitin sulfates, hyaluronic acid, curdlan, chitosan, deacetylated konjac, and rhizobium gum.
  • [0060]
    In embodiments of the invention, the hydrocolloid may be a water soluble non-gelling polypeptide or protein exemplified by gelatins, albumins, milk proteins, soy protein, and whey proteins. The hydrocolloid may further be selected from a group of synthetic hydrocolloids exemplified by any of the following: polyethylene-imine, hydroxyethyl cellulose, sodium carboxymethyl cellulose, carboxymethyl cellulose, hydroxypropyl cellulose, hydroxypropyl methyl cellulose, methyl cellulose, ethyl cellulose, polyacrylic acids, low molecular weight polyacrylamides and their sodium salts (carbomers), polyvinylpyrrolidone, polyethylene glycols, polyethylene oxides, polyvinyl alcohols, pluronics, tetronics, and other block co-polymers, carboxyvinyl polymers, and colloidal silicon dioxide. A preferred embodiment of the invention utilizes a hydroxypropyl methyl cellulose having a methoxy content of about 19-30% and hydroxypropyl content of 7-12% and a molecular weight of approximately 50,000-250,000 daltons (Table 9).
  • [0061]
    In addition to hydrocolloids and the active agents, the films may contain any or all of the following ingredients: emulsifying agents, solubilizing agents, wetting agents, taste modifying agents, plasticizers, active agents, water soluble inert fillers, preservatives, buffering agents, coloring agents, and stabilizers. In a preferred embodiment, the percentage dry weight concentration of at least single ingredients incorporated in a film in each of the following categories is as follows: emulsifying agent (0.1%-10%), plasticizer (0.5-20%), active agents (0.01-75%), taste modifying agents (0.1-10%), coloring agents (0.01-5%), water soluble inert fillers (0.5-50%), preservatives (0.01-10%), buffering agents (0.1-10%) and stabilizers (0.01-5%.
  • [0062]
    Methods for manufacturing the dosage unit of the invention include the solvent casting methods as shown in FIG. 2 or alternatively extrusion methods as exemplified in Example 11. The extrusion method involves blending ingredients to form a film using mechanical force and moderate heat. Significantly, the above processes do not rely on a freeze drying step. Nor do the above processes rely on extremes of heat or cold during manufacture.
  • [0063]
    In an embodiment of the invention, the solvent casting method includes a natural or synthetic hydrocolloid that is completely dissolved or dispersed in water or in a water alcoholic solution under mixing to form a homogenous formulation. In addition to the active agent and the hydrocolloid, any of the ingredients listed above may be added and dispersed or dissolved uniformly in the hydrocolloid solution. The active ingredients and flavoring agents can be incorporated before or after film forming. This homogeneous mixture (coating solution) with a solid content of 5-50% and a viscosity of 500-15000 cps was degassed (8) and coated on the non-siliconized side of a polyester film (10) at 5-50 mil wet film thickness (9), more preferably 5-20mil wet film thickness and dried under aeration at a temperature between 40-100° C. so as to avoid destabilizing the agents contained within the formulation (11). The manufacturing process for forming the dosage unit is illustrated in FIG. 2. The dry film formed by this process is a glossy, stand alone, self supporting, non-tacky and flexible film (12). The dry film is then cut into a suitable shape (13) and surface area for active agent delivery at the preferred site. For example, the cast film can be die-cut into different shapes and sizes using a rotary die. The film may be cut into a size that contains for example, a single dosage unit. For example, a dosage unit may include a film size with surface area of 5cm2 that contains a dosage of active agent in the range of 20-250 mg (14). The size of the film may be varied according to the dosage required. The dosage contained in each square centimeter is selected according to the active agent. Films are then packaged into a single pouch package, multi-unit blister card or multiple unit dispensers (FIG. 3).
  • [0064]
    In contrast to the above method, the dry extrusion method does not rely on placing the hydrocolloid in a solvent. Instead, the ingredients of the dosage unit are mixed together in dry form and heated. The heated blend is then forced through an extrusion die to form a film of selected thickness. The film can then be cut and packaged.
  • [0065]
    The dry extrusion method has a number of advantages. First, it is an economical process. Second, because there is no drying oven, extrusion of the film is faster than solvent coating. Third, the dry extrusion avoids the step of removing residual solvent. Some residual solvent is generally present in the solvent coating process and can affect the safety or stability of the film. Where a film requires an organic solvent rather than water, removal of the solvent from the film may be required by environmental regulations. The extrusion process avoids any need for recovering solvent and avoids residual solvent in the film.
  • [0066]
    The dosage unit may be prepared for use by selecting a film that is capable of delivering an effective dose and administering the film to the patient by placing it on a mucosal surface such as the oral mucosa (FIG. 1) where it dissolves in the body fluid for example, saliva (0.5-10 minutes) and is swallowed in liquid form. FIG. 4 graphically represents the rate of disintegration and dissolution for different thickness films. FIG. 5 shows the release profile of four active agents from films according to Examples 5-8. The fraction of the dose absorbed through the mucosal tissue can be facilitated by the use of a permeation enhancer into the film.
  • [0067]
    The overall bioavailability of the active agent which is absorbed both locally at the mucous membrane and systemically within the gastrointestinal system is improved compared to the same dose of the active agent given in a conventional oral tablet or capsule dosage form. This is exemplified in FIG. 6 and Table 11 which show the improved bioavailability of Sildenafil film over Viagra. The oral retention characteristics, mouth feel properties, flavor and taste of the film can be modified based on the hydrocolloid and other excipients used to prepare the films and the medications.
  • [0068]
    The invention is illustrated but not meant to be limited to the examples provided below. According to Examples 1-8, the hydrocolloid was dissolved in water under agitated mixing to form a uniform and viscous solution. Additional ingredients were then added sequentially to the viscous solution such as peppermint, aspartame, propyl glycol, benzoic acid and citric acid under agitated mixing until they were uniformly dispersed or dissolved in the hydrocolloid. The resultant mixture was degassed in a vacuum chamber until trapped air bubbles were removed.
  • [0069]
    The viscosity, pH and specific gravity were measured. The formulation was then coated on the non-siliconized side of a polyester film at a wet thickness of 10 mil and dried in a hot air circulating oven at 50° C. for 9 minutes. A glossy, substantially transparent, stand alone, self-supporting, non-tacky and flexible film was obtained after drying. The dry film was cut into different shapes for measurement of dry tack, wet tack, tensile strength modulus, elongation, tear resistance, residual water content, disintegration and dissolution. The dosage form was 25-250 mg in various shapes, sizes, and thickness.
  • [0070]
    Example 9 shows how the properties of dosage units vary when different hydroxymethylcellulose polymers are utilized. Example 10 shows how mucoadhesion can be increased up to at least 84% using an enhancer exemplified by starch graft copolymer.
  • [0071]
    In vivo studies of the dosage unit show that it is well tolerated by patients (Example 12) and shows enhanced bioavailability (Example 13)
  • EXAMPLES
  • [0072]
    Examples 1-3
  • Quick dissolving Films, Compositions and Associated Properties
  • [0073]
    The films were prepared as follows: a homogeneous mixture of ingredients was prepared in a coating solution in the amounts indicated in Table 1. The amounts are given as percentage weight of coating solution. The mixture was degassed in a vacuum chamber and coated on the non-siliconized side of a polyester film and dried in a hot air circulating oven to form a self supporting non-tacky and flexible film. The film was then cut into dosage units ready for packaging.
    TABLE 1
    Formulation of quick dissolving films using
    several different hydrocolloids.
    Composition: coating solution % Ex. 1 Ex. 2 Ex. 3
    Pullalan (P-20) w % 17.5
    Methocel E5 w % 21.06
    POLYOX WSR N-10 w % 1.8
    PVA (Vinol 125) w % 1.5
    Cellulose gum w % 8.1
    Propylene glycol w % 1.0 2.5
    Aspartame w % 0.8 0.475 0.46
    Peppermint w % 1.0 1.0 0.6
    Citric acid w % 0.7 0.8
    Cremphor EL40 w % 1.0 1.0
    Benzoic acid w %  0.013 0.1 0.01
    FD&C blue #1 w % qs.
    FD&C yellow #5 w % qs.
    Ethanol w % 10.6
    Water w % 74.42 67.025 85.6
  • [0074]
    [0074]
    TABLE 2
    Properties of the film formed from the coating solution of Table 1.
    Properties of dry film Ex. 1 Ex. 2 Ex. 3
    Thickness (mil) 2.1 2.5 2.6
    Water content % 1.7 8.5 8.0
    Dry tack (g) 0.67 0.55 0.60
    Wet tack (g) 60.16 86.64 72.27
    Tensile strength (psi) 5242 2381 2036
    % Elongation (sec) 2.9 4 2.9
    Modulus (psi) 266834 272502 44566
    Tear resistance (N) 0.02 0.16 0.01
    Disintegration (sec) 12 20 12
    Dissolving time (sec) 41 60 39
  • [0075]
    [0075]
    TABLE 3
    Dry weight percentages for components of
    Example 1 according to Tables 1 and 2
    Ingredients Percentage (w/w)
    Methocel E5 82.35 
    Propylene glycol 3.91
    Aspartame 3.13
    Citric acid 2.74
    Peppermint oil 3.91
    PEG-40 Hydrogenated castor oil 3.91
    Benzoic acid 0.5 
    FD&C blue #1 qs.
    FD&C yellow #5 qs.
  • [0076]
    [0076]
    TABLE 4
    Mean values for parameters according to Example 1 in Table 1.
    Properties Value + SD (n)
    Weight (g/dosage film) 0.028 0.001 (4)
    Thickness (mil) 2.1 0.12 (3)
    PH 3.07 (1)
    Density (g/cm2) 1.0485 0.009 (3)
    % Water content 1.7 0.24 (2)
    Dry tack (g) 0.674 0.110 (6)
    Wet tack (g) 60.169 11.680 (6)
    tensile strength (psi) 5242 379 (5)
    % Elongation 2.9 0.4 (5)
    Modulus (psi) 266834 7910 (5)
    Tear-propagation resistance (N) 0.02 0.00 (4)
    Disintegration time (sec) 12 1 (3)
    Dissolving time (sec) 41 5 (3)
  • Examples 4-8 Hydropropylmethylcellulose based Quick Dissolving Intraoral Film Containing Therapeutic Agents
  • [0077]
    The films were prepared according to Examples 1-3. Therapeutic agents were added to the homogeneous mixture (coating solution) prior to forming the film.
    TABLE 5
    Composition
    (coating solution) Ex. 4 Ex. 5 Ex. 6 Ex. 7 Ex. 8
    Nicotine 1.4
    Hydromorphone 2.92
    Oxybutynin 3.71
    Estradiol 1.49
    Peppermint 1.0 1.0 1.0 1.0 1.0
    Methocel E5 (HPMC) 21.06 21.06 21.06 21.06 21.06
    Propylene glycol 1.0 1.0 1.01 1.0 1.0
    Aspartame 0.8 0.8 0.8 0.8 0.8
    Citric acid 0.7 0.7 0.7 0.7 0.7
    Cremphor EL40 1.0 1.0 1.0 1.0 1.0
    Benzoic acid  0.013 0.013 0.013 0.013 0.013
    FD&C blue #1 qs.
    FD&C yellow #5 qs.
    Water 74.43 73.03 71.51 70.72 72.94
  • [0078]
    [0078]
    TABLE 6
    Properties of the film formed according to the formulation in Table 5
    Properties Ex. 4 Ex. 5 Ex. 6 Ex. 7 Ex. 8
    Thickness (mil) 3.0 2.9 2.9 3.2 2.7
    Density (g/cm3) 1.18 1.19 1.13 1.20 1.16
    Water content % 1.8 2.93 2.42 2.32 2.31
    Dry tack (g) 0.67 0.608 0.619 1.215 0.671
    Wet tack (g) 49.08 54.81 84.34 88.85 39.91
    Tensile strength (psi) 4393 3373 4138 3549 3688
    % Elongation (sec) 8.3 8.3 7.6 8.1 7.5
    Modulus (psi) 45969 48168 42110 41745 53334
    Tear resistance (N) 0.03 0.02 0.01 0.03 0.01
    Disintegration (sec) 43.0 34.3 27.3 36.0 55.7
    Dissolving time (sec) 73.7 64.3 58.0 65.7 111.3
  • [0079]
    [0079]
    TABLE 7
    Composition of the Sildenafil film (% wet base)
    Composition Percentage
    Sildenafil citrate 28.93
    Xylitol 3.21
    Methocel E15 4.59
    Propylene Glycol 3.67
    Aspartame 0.46
    Benzoic acid 0.0045
    Peppermint oil 0.46
    Sodium EDTA 0.0045
    Polyoxamer L-44 2.3
    Water 55
    Polypro 5000 0.92
  • [0080]
    [0080]
    TABLE 8
    Properties of the film formed according to the formulation in Table 7
    Properties Ex. 9
    Thickness 3.2 ± 0.1
    Density (g/cm3) 1.230
    Dry tack (g) 1.21 ± 0.19
    Wet tack (g) 23.79 ± 3.45 
    Tensile strength (psi) 421 ± 49 
    % Elongation 4.0 ± 0.7
    Modulus (psi) 31822 ± 6137 
    Tear resistance (N) 0.04 ± 00  
    Disintegration (sec) 8.3 ± 1.5
    Dissolution (sec) 23.7 ± 1.5 
  • [0081]
    Table 9: A comparison of properties of dosage units using different hydroxypropyl-methylcellulose polymers
  • [0082]
    The properties of a dosage unit according to the invention may be modified by varying individual components. For example, the dissolution of the film may be prolonged by using hydroxypropylmethylcellulose (BPMC) with higher molecular weight as shown below in Table 9.
    TABLE 9a
    Properties of selected commercial hydroxypropylmethylcellulose polymers.
    Methocel Type (Dow Pharmaceuticals)
    Property E3 E5 K3 E15 A15 E50 F50
    % Methoxyl 29 29 22 29 30 29 28
    % Hydroxypropyl   8.5   8.5   8.1   8.5  0   8.5   5.0
    Viscosity 2% (cps) 2-4 4-6 2-4 12-18 12-18 40-60 40-60
  • [0083]
    [0083]
    TABLE 9b
    Properties of films prepared according to Example 1, using different hydroxypropyl-
    methylcellulose polymers
    Property E3 E5 K3 E15 A15 E50 F50
    Dry tack (g) 0.61 ± 0.08  0.67 ± 0.110  0.82 ± 0.12 0.66 ± 0.09 0.52 ± 0.09 0.68 ± 0.14 0.52 ± 0.12
    Wet tack (g) 93.4 ± 8.95 60.169 ± 11.6   60.2 ± 8.77 65.4 ± 17.8 18.4 ± 3.0  79.1 ± 17.1 64.1 ± 11.2
    Tensile strength 1921 ± 442  5242 ± 379 2043 ± 268 4316 ± 384  3351 ± 165  3725 ± 123  3905 ± 590 
    (psi)
    % Elongation 4.2 ± 1.2  2.9 ± 0.4  3.8 ± 0.8 16.9 ± 4.3  11.1 ± 2.4  11.4 ± 2.4  15.0 ± 3.4 
    Modulus (psi) 44368 ± 864  266834 ± 79   41737 ± 816  46889 ± 416  35914 ± 964  41651 ± 282  43644 ± 942 
    Tear resistance (N) 0.040.01 ±       0.02 ± 0    0.05 ± 0.01 0.09 ± 0.03 0.12 ± 0.02 0.05 ± 0.01 0.08 ± 0.01
    Disintegration (sec) 17.0 ± 4.4  12 ± 1 15.3 ± 1.5 21.9 ± 1.6  161.0 ± 15.9  33.2 ± 5.1  24.1 ± 1.3 
    Dissolution (sec) 35.7 ± 2.1  41 ± 5 31.0 ± 1.0 51.6 ± 1.3  >600 71.6 ± 3.3  62.1 ± 2.8 
  • Example 10 Enhancement of Mucoadhesion
  • [0084]
    The enhancement of mucoadhesion was similarly applicable to films of varying thickness. The following formulations were prepared:
    TABLE 10
    Composition/Test results Example 1 Example 10a Example 10b
    Composition of example 1 100%  99.9% 95%
    Starch graft copolymer•  0  0.1% 0  5%
    Mean Mucoadhesion  17.5  26.6 32.3
    measurement (g)••
    Standard deviation  7.8  4.7  4.0
    Increase in mucoadhesion % base value 525 84.6%
    # grams force (g or gf). Test conditions used are follows: speed of application = 3 mm/s, speed of detachment = 2 mm/s, force applied before detachment = 150 g, contact time = 5 s, contact surface = 122.7 mm2
  • Example 11 Preparation of Film Using Dry Extrusion Techniques
  • [0085]
    77.8 g Plyetheylene Oxide (Polyox® WSR N-10) was mixed using mechanical force and additional ingredients were added during the mixing as follows: 5.5 g Estradiol, 3.7 g Peppermint, 3.7 g Propylene Glycol, 3.0 g Aspartame, 2.6 g Citric Acid, 3.7g Cremphor EL 40 and 0.05 g Benzoic acid. The temperature was maintained at about 70° C.
  • [0086]
    The blend was allowed to mix at 70° C. until uniform. It was then forced through an extrusion die to form a film 5 mils in thickness. The film was then cut into dosage forms ready for packaging.
  • Example 12 HUMAN CLINICAL ACUTE IRRITATION STUDY
  • [0087]
    An initial clinical irritation study of placebo samples formulated according to Example 1 was conducted. Six HPMC-based films were applied by each of 12 subjects within one hour. The site of application and the oral mucosae were evaluated for any acute irritation prior to each application, immediately after each application, one hour and 24 hours after last application. The following indications: erythema, edema, bullae, maceration and discharge were scored on a scale of 0-4. There was no measurable irritation for any of the sites examined and for any of the indications during each application, or one hour and 24 hours after the last application.
  • [0088]
    Each subject was asked to assess the mouth feel, product taste, sensation and dissolution time for each application. All subjects described films gave them very smooth mouth feel and indicated the taste of freshness the film delivered into the oral cavity for each application. All subjects felt the dissolution time of the film was very short (<2 min).
  • [0089]
    The majority of the subjects states a preference for the film compared with tablets or capsules. All of the subjects indicated that they preferred the film to solutions or syrups.
  • Example 13 Human Pharmacokinetics Study Showing Increased Bioavailability of an Active Agent Delivered by a Dosage Unit in the Form of a Film
  • [0090]
    A dissolving film suitable for administration via the oral mucosa and containing the active agent, sildenafil citrate, formulated according to Table 7. The properties of the dosage unit are described in Table 8.
  • [0091]
    A two way crossover study was conducted comparing intraoral sildenafil, applied sublingually, with a commercial table (Viagra® at the same dosage. The average plasma levels and the pharmacokinetics analysis are displayed in FIG. 6 and Table 11. FIG. 6 and Table 11 show that the bioavailability of the equivalent dosage from the dissolving film is about 25% higher than the bioavailability of the table.
    TABLE 11
    A comparison of pharmacokinetic parameters
    of Sildanedil film and Viagra film
    Sildanefil (S) Statistical
    Parameters film Viagra (V) film Ratio S/V power
    AUC*(99-t) 365.5 293.1 1.247 0.86
    AUC (infinity) 378 310.4 1.218 .088
    Cmax 109.9 106.8 1.029 0.15
    Tmax 1 1 1 0.08
    Ke 0.354 0.285 1.245 0.32
    t 1.992.56 0.775 0.775 0.23
  • [0092]
    The present invention having been disclosed in connection with the foregoing embodiments, additional embodiments will now be apparent to persons skilled in the art. The present invention is not intended to be limited to the embodiments specifically mentioned, and accordingly reference should be made to the appended claims rather than the foregoing discussion, to assess the spirit and scope of the present invention in which exclusive rights are claimed.
Referenced by
Citing PatentFiling datePublication dateApplicantTitle
US7279457Mar 11, 2005Oct 9, 2007Biodel, Inc.Rapid acting drug delivery compositions
US7648960Nov 21, 2003Jan 19, 2010Mannkind CorporationMethod for delivery of monomeric or dimeric insulin complexed to diketopiperazine microparticles
US7691986Apr 23, 2003Apr 6, 2010Nanotherapeutics, Inc.High molecular weight, low methoxyl pectins, and their production and uses
US7705135May 19, 2006Apr 27, 2010Nanotherapeutics, Inc.Pharmaceutical compositions comprising aloe pectins, and methods for their production and use
US7713929Apr 2, 2007May 11, 2010Biodel Inc.Rapid acting and long acting insulin combination formulations
US7718609Apr 11, 2007May 18, 2010Biodel Inc.Rapid acting and long acting insulin combination formulations
US7910641Dec 14, 2006Mar 22, 2011Monosol Rx, LlcPH modulated films for delivery of actives
US7943178Dec 10, 2009May 17, 2011Mannkind CorporationMethods and compositions for delivering peptides
US8084420Dec 27, 2011Biodel Inc.Rapid acting and long acting insulin combination formulations
US8389470Jan 5, 2011Mar 5, 2013Mannkind CorporationMethods and compositions for delivering peptides
US8394414Nov 12, 2003Mar 12, 2013Mannkind CorporationMethod for drug delivery to the pulmonary system
US8652378Mar 29, 2013Feb 18, 2014Monosol Rx LlcUniform films for rapid dissolve dosage form incorporating taste-masking compositions
US8747005Jun 4, 2008Jun 10, 2014Colgate-Palmolive CompanyOral care implement with cavitation system
US8765167Sep 8, 2006Jul 1, 2014Monosol Rx, LlcUniform films for rapid-dissolve dosage form incorporating anti-tacking compositions
US8900497Aug 23, 2013Dec 2, 2014Monosol Rx, LlcProcess for making a film having a substantially uniform distribution of components
US8900498Aug 23, 2013Dec 2, 2014Monosol Rx, LlcProcess for manufacturing a resulting multi-layer pharmaceutical film
US8906277Aug 23, 2013Dec 9, 2014Monosol Rx, LlcProcess for manufacturing a resulting pharmaceutical film
US8933023Jan 15, 2014Jan 13, 2015Biodel Inc.Rapid acting injectable insulin compositions
US9006175Jan 10, 2006Apr 14, 2015Mannkind CorporationPotentiation of glucose elimination
US9060927Mar 3, 2009Jun 23, 2015Biodel Inc.Insulin formulations for rapid uptake
US9108340Aug 23, 2013Aug 18, 2015Monosol Rx, LlcProcess for manufacturing a resulting multi-layer pharmaceutical film
US9192675Jul 30, 2013Nov 24, 2015Mankind CorporationDry powder inhaler and system for drug delivery
US9220687Nov 7, 2014Dec 29, 2015Mannkind CorporationSubstituted diketopiperazine analogs for use as drug delivery agents
US9233159Oct 24, 2012Jan 12, 2016Mannkind CorporationMethods and compositions for treating pain
US9241903Jul 15, 2013Jan 26, 2016Mannkind CorporationMethod for improving the pharmaceutic properties of microparticles comprising diketopiperazine and an active agent
US9283193Apr 10, 2014Mar 15, 2016Mannkind CorporationMethod of drug formulation based on increasing the affinity of crystalline microparticle surfaces for active agents
US9339615Mar 14, 2013May 17, 2016Mannkind CorporationDry powder inhaler and system for drug delivery
US20030220485 *Apr 23, 2003Nov 27, 2003Carrington Laboratories, Inc.High molecular weight, low methoxyl pectins, and their production and uses
US20040077528 *Nov 21, 2003Apr 22, 2004Mannkind CorporationPurification and stabilization of peptide and protein pharmaceutical agents
US20040096403 *Nov 12, 2003May 20, 2004Mannkind CorporationMethod for drug delivery to the pulmonary system
US20050075432 *Oct 7, 2003Apr 7, 2005Verrall Andrew P.Acidulent film and method of making same
US20050088617 *Oct 27, 2003Apr 28, 2005Jen-Chuen HsiehMethod and apparatus for visual drive control
US20050153874 *Jan 10, 2005Jul 14, 2005Mannkind CorporationMethod of reducing serum proinsulin levels in type 2 diabetics
US20050214251 *Mar 11, 2005Sep 29, 2005Biodel, Inc.Rapid acting drug delivery compositions
US20060171960 *Dec 29, 2005Aug 3, 2006WyethMethods and composition for oral vaccination
US20060222708 *Mar 28, 2006Oct 5, 2006Markus KrummeWafer comprising steroid hormones
US20070086952 *Sep 29, 2006Apr 19, 2007Biodel, Inc.Rapid Acting and Prolonged Acting Inhalable Insulin Preparations
US20070112593 *Feb 7, 2006May 17, 2007Rxcera Pharmaceutical, Inc.Selection system, dispensing system and treatment with a one-a-day combination pill for hypertension, hypercholesterolemia, hypertriglyceridemia and anti-platelet treatment
US20070190117 *Apr 23, 2004Aug 16, 2007Bodo AsmussenBuccal formulations of galanthamine and uses thereof
US20070235365 *Jun 25, 2007Oct 11, 2007Biodel Inc.Rapid Acting Drug Delivery Compositions
US20070292479 *Jan 24, 2007Dec 20, 2007Hans-Peter PodhaiskyFilm-shaped drug forms for use in the oral cavity (wafers)
US20080039368 *Apr 11, 2007Feb 14, 2008Biodel Inc.Rapid acting and long acting insulin combination formulations
US20080085298 *Oct 9, 2007Apr 10, 2008Biodel, Inc.Rapid Mucosal Gel or Film Insulin Compositions
US20080090753 *Oct 9, 2007Apr 17, 2008Biodel, Inc.Rapid Acting Injectable Insulin Compositions
US20080096800 *Oct 24, 2007Apr 24, 2008Biodel, Inc.Rapid mucosal gel or film insulin compositions
US20080248999 *Apr 3, 2008Oct 9, 2008Biodel Inc.Amylin formulations
US20090017085 *Oct 27, 2004Jan 15, 2009Francesco CilurzoSelf-supporting films for pharmaceutical and food use
US20090047330 *Oct 9, 2008Feb 19, 2009Ramesh BangaloreOral fast dissolving films for erectile dysfunction bioactive agents
US20090047350 *Aug 14, 2008Feb 19, 2009Ramesh BangalorePerforated water soluble polymer based edible films
US20090137455 *Nov 26, 2008May 28, 2009Biodel Inc.Rapid acting and long acting insulin combination formulations
US20090175840 *Jan 5, 2009Jul 9, 2009Biodel, Inc.Insulin formulations for insulin release as a function of tissue glucose levels
US20090192075 *Jul 30, 2009Biodel Inc.Amylin Formulations
US20100021526 *Jan 28, 2010Monosol Rx, LlcPh modulated films for delivery of actives
US20100086609 *Apr 8, 2010Mannkind CorporationMethods and Compositions for Delivering Peptides
US20100100391 *Sep 30, 2009Apr 22, 2010Kantilal Kasan DayaPharmaceutical packaging and method for delivery of same
US20100227795 *Sep 9, 2010Biodel Inc.Insulin formulations for rapid uptake
US20100275394 *Jun 4, 2008Nov 4, 2010James Herbert KempOral Care Implement With Cavitation System
US20100305975 *May 28, 2010Dec 2, 2010Kantilal Kasan DayaPharmaceutical Packaging and Method for Delivery of Same
US20110052699 *Feb 10, 2009Mar 3, 2011Adrian FunkeDrug delivery system with stabilising effect
US20110097405 *Feb 5, 2009Apr 28, 2011Bayer Schering Pharma AktiengesellschaftEstradiol-containing drug delivery system
US20110105391 *Jan 5, 2011May 5, 2011Mannkind CorporationMethods and Compositions for Delivering Peptides
US20140286876 *Mar 28, 2014Sep 25, 2014Andrew L. SKIGENVeterinary active agent application
EP2106790A1 *Mar 11, 2005Oct 7, 2009Biodel, Inc.Rapid acting drug delivery compositions
EP2319500A1 *Mar 11, 2005May 11, 2011Biodel, Inc.Rapid acting drug delivery compositions
WO2005035776A2 *Oct 6, 2004Apr 21, 2005Monosol, LlcAcidulent film and method of making same
WO2005035776A3 *Oct 6, 2004Jul 7, 2005Monosol LlcAcidulent film and method of making same
WO2005089722A1 *Mar 11, 2005Sep 29, 2005Biodel, Inc.Rapid acting drug delivery compositions
WO2007075422A2 *Dec 14, 2006Jul 5, 2007Monosol Rx, LlcPh modulated films for delivery of actives
WO2007075422A3 *Dec 14, 2006Mar 20, 2008Monosoirx LlcPh modulated films for delivery of actives
WO2009101021A2 *Feb 5, 2009Aug 20, 2009Bayer Schering Pharma AktiengesellschaftEstradiol-containing drug delivery system
WO2009101021A3 *Feb 5, 2009Dec 30, 2009Bayer Schering Pharma AktiengesellschaftEstradiol-containing drug delivery system
Classifications
U.S. Classification424/486
International ClassificationA61K31/465, A61P31/12, A61K31/216, A61P15/10, A61K31/519, A61K9/70, A61K31/485, A61K47/36, A61K47/30, A61P31/10, A61P31/04, A61P15/18, A61K47/42, A61K47/38, A61K31/565, A61K47/10, A61K9/48, A61P1/02, A61K, A61K31/495, A61K9/46, A61K31/505, A61K9/00, A61K9/14, A61K9/16
Cooperative ClassificationA61K31/505, A61K9/0031, A61K9/0043, A61K9/0034, A61K31/495, A61K9/006, A61K9/1623, A61K9/0056, A61K9/7007, A61K9/145, A61K9/7015, A61K9/0007
European ClassificationA61K9/00M18B, A61K31/505, A61K9/00M6, A61K9/70D, A61K9/70B, A61K9/00M18D, A61K9/00M8, A61K31/495, A61K9/00M14, A61K9/16H4B, A61K9/14H4, A61K9/00L6
Legal Events
DateCodeEventDescription
May 14, 2002ASAssignment
Owner name: LAVIPHARM LABORATORIES INC., NEW JERSEY
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:CHEN, LI-LAN H.;PFISTER, WILLIAM R.;RENN, DONALD W.;AND OTHERS;REEL/FRAME:012901/0194;SIGNING DATES FROM 20020412 TO 20020424
Jan 23, 2006ASAssignment
Owner name: MEDICAL PROVIDER FINANCIAL CORPORATION, III, CALIF
Free format text: SECURITY AGREEMENT;ASSIGNOR:LAVIPHARM LABORATORIES, INC.;REEL/FRAME:017050/0835
Effective date: 20060109
Jan 28, 2016ASAssignment
Owner name: THALLIUM HOLDING COMPANY, LLC, MASSACHUSETTS
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNOR:LAVIPHARM LABORATORIES, INC.;REEL/FRAME:037610/0699
Effective date: 20160113
Owner name: THALLIUM HOLDING COMPANY, LLC, MASSACHUSETTS
Free format text: ASSIGNMENT OF SECURITY INTEREST;ASSIGNOR:MEDICAL PROVIDER FINANCIAL CORPORATION, III;REEL/FRAME:037627/0778
Effective date: 20151112